Recommendations from the Advisory Committee on Immunization Practices (ACIP) for the 2017-18 flu season can be accessed here.
- Routine annual influenza vaccination of all persons continues to be recommended.
- No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended product is otherwise appropriate.
- All 2017-18 trivalent (3-component) vaccines protect against these strains:
- A/Michigan/45/2015 (H1N1)pdm09–like virus (new for 2017-18)
- A/Hong Kong/4801/2014 (H3N2)-like virus
- B/Brisbane/60/2008-like virus (Victoria lineage)
- In addition to the 3 strains in the trivalent vaccine, the quadrivalent vaccine also protects against B/Phuket/3073/2013-like virus (B/Yamagata lineage).
- Live attenuated influenza vaccine (LAIV4) should still not be used, due to low effectiveness during prior flu seasons.
- Recommendations for influenza vaccination of persons with egg allergies have not changed from the 2016-17 season.
- Vaccination should begin as soon as vaccine is available with special emphasis on people with conditions that put them at increased risk for complications from influenza.